Cooper Companies (NASDAQ:COO) Price Target Raised to $101.00

Cooper Companies (NASDAQ:COO) had its price target lifted by investment analysts at Needham & Company LLC from $99.00 to $101.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. Needham & Company LLC’s price target suggests a potential upside of 25.94% from the company’s previous close.

Several other research analysts also recently weighed in on the company. JPMorgan Chase & Co. upped their target price on Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, December 5th. Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Stifel Nicolaus set a $95.00 price objective on shares of Cooper Companies and gave the company a “buy” rating in a report on Friday, December 5th. Rothschild & Co Redburn cut shares of Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 target price for the company. in a research note on Wednesday. Finally, Wells Fargo & Company upped their price target on shares of Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.50.

Cooper Companies Trading Down 2.2%

COO stock opened at $80.20 on Friday. The company’s 50-day simple moving average is $82.23 and its 200-day simple moving average is $75.95. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30. Cooper Companies has a 52-week low of $61.78 and a 52-week high of $91.59. The firm has a market cap of $15.65 billion, a P/E ratio of 42.66, a PEG ratio of 2.34 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, March 5th. The medical device company reported $1.10 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.07. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.Cooper Companies’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.92 EPS. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. As a group, equities analysts forecast that Cooper Companies will post 3.98 EPS for the current fiscal year.

Insider Activity

In other Cooper Companies news, CEO Albert G. White III acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was bought at an average price of $80.80 per share, with a total value of $808,000.00. Following the purchase, the chief executive officer owned 236,151 shares in the company, valued at approximately $19,081,000.80. The trade was a 4.42% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Maria Rivas acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 18th. The stock was acquired at an average price of $82.13 per share, with a total value of $82,130.00. Following the acquisition, the director owned 11,141 shares in the company, valued at $915,010.33. The trade was a 9.86% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 16,014 shares of company stock valued at $1,304,416 in the last ninety days. 2.08% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cooper Companies

A number of institutional investors have recently added to or reduced their stakes in COO. Vanguard Group Inc. increased its stake in shares of Cooper Companies by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company’s stock worth $1,725,963,000 after acquiring an additional 421,423 shares during the last quarter. Capital World Investors boosted its position in shares of Cooper Companies by 25.7% during the 3rd quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock valued at $723,417,000 after acquiring an additional 2,159,233 shares during the last quarter. State Street Corp grew its holdings in shares of Cooper Companies by 2.4% in the fourth quarter. State Street Corp now owns 8,793,747 shares of the medical device company’s stock valued at $720,736,000 after purchasing an additional 207,195 shares during the period. Wellington Management Group LLP increased its position in Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock worth $424,043,000 after purchasing an additional 4,756,178 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Cooper Companies by 58.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock worth $494,123,000 after purchasing an additional 2,231,568 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Company raised full‑year 2026 EPS and free‑cash‑flow guidance, citing strong momentum for MyDay and MiSight contact‑lens franchises — a clear upside catalyst for revenue and cash generation expectations. Article Title
• Positive Sentiment: Q1 results beat EPS estimates: reported $1.10 EPS vs. ~ $1.03 consensus; revenue roughly $1.02B (+6.2% YoY) with improved margins and stronger operating cash flow — supports the raised guidance. Press Release
• Positive Sentiment: Product/clinical momentum: CooperVision highlighted research at NCC 2026 supporting long‑term comfort and wear for contact lenses — bolsters competitive positioning for MyDay/MiSight adoption. PR
• Positive Sentiment: Insider buying activity flagged by data services (multiple recent insider purchases) — can be read as management confidence in outlook. QuiverQuant
• Neutral Sentiment: Full earnings call transcript and slide deck released — useful for investors who want line‑by‑line detail on regional trends, product growth and cadence of guidance. Transcript
• Neutral Sentiment: Investing press pieces highlight a strategic‑review focus at the company — could signal future capital allocation or portfolio moves but timing/impact are uncertain. Investing.com
• Negative Sentiment: Rothschild & Co Redburn downgraded COO from Buy to Neutral with an $85 price target — an analyst downgrade that can pressure the stock despite the outlook upgrade. Finviz

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.